9,514 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Allstate Corp

Allstate Corp bought a new position in Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 9,514 shares of the company’s stock, valued at approximately $396,000.

A number of other hedge funds also recently added to or reduced their stakes in MRNA. Cerity Partners LLC boosted its stake in Moderna by 7.0% during the 3rd quarter. Cerity Partners LLC now owns 13,769 shares of the company’s stock valued at $920,000 after purchasing an additional 900 shares during the period. Quantbot Technologies LP acquired a new position in shares of Moderna during the third quarter worth approximately $150,000. Townsquare Capital LLC grew its holdings in Moderna by 42.7% in the 3rd quarter. Townsquare Capital LLC now owns 5,288 shares of the company’s stock worth $353,000 after buying an additional 1,583 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in Moderna by 18.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 16,380 shares of the company’s stock worth $1,095,000 after buying an additional 2,500 shares in the last quarter. Finally, Benjamin Edwards Inc. increased its position in Moderna by 14,009.7% in the 3rd quarter. Benjamin Edwards Inc. now owns 4,374 shares of the company’s stock valued at $292,000 after acquiring an additional 4,343 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on MRNA. JPMorgan Chase & Co. decreased their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Leerink Partners lowered their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $59.00.

Moderna Trading Up 2.1 %

Shares of MRNA stock opened at $27.72 on Thursday. The stock’s fifty day simple moving average is $34.21 and its 200-day simple moving average is $43.44. The company has a market capitalization of $10.72 billion, a price-to-earnings ratio of -2.99 and a beta of 1.86. Moderna, Inc. has a 1-year low of $26.26 and a 1-year high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.